Natalizumab use during the third trimester of pregnancy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Natalizumab reduces multiple sclerosis relapses very effectively; however, severe disease activity may return once natalizumab treatment is withdrawn, as recommended during pregnancy. Sometimes restarting natalizumab treatment may be the best option for the mother, but the consequences for the infant are unknown. Except for a few single case reports, to our knowledge, comprehensive data about third-trimester natalizumab exposure are scant.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA Neurol

Title: JAMA neurology

ISSN (Electronic): 2168-6157

ISSN (Print): 2168-6149

Publication date (Electronic): Jul 1 2014

Volume: 71

Issue: 7

Affiliations

[1 ] Department of Neurology, St Josef-Hospital, Ruhr University Bochum, Bochum, Germany.

[2 ] Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena.

[3 ] Department of General Pediatrics, University Children's Hospital Münster, Münster, Germany.

[4 ] University Children's Hospital Mannheim, Heidelberg University, Heidelberg, Germany.

[5 ] Neurologic Practice Hamburg, Hamburg, Germany.

[6 ] Neurologic Practice Barsinghausen, Barsinghausen, Germany.

[7 ] Department of Neurology, University of Bonn, Bonn, Germany.

[8 ] Faculty of Pharmacy, University of Dusseldorf, Dusseldorf, Germany.

[9 ] Department of Neurology, kbo-Isar-Amper-Klinikum München-Ost, Munich, Germany.

[10 ] Institute for Clinical Neuroimmunology, Ludwig-Maximilians-University, Munich, Germany.

[11 ] Biogen Idec, Cambridge, Massachusetts.

[12 ] Department of Neurology, St Josef-Hospital, Ruhr University Bochum, Bochum, Germany2Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena.

Article

Publisher Item ID: 1867507

DOI: 10.1001/jamaneurol.2014.209

PubMed ID: 24821217

SO-VID: e5938321-b31c-4f2b-9727-d71b05294b7b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 57

See all cited by

- Version 1